Clinical Trial

Duodenal pulsENDO for Suboptimally Controlled Type II Diabetes Mellitus and Steatotic Liver Disease

Study acronym: DRESS-1
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
This study is designed to evaluate the efficacy, safety, and mechanisms of pulsENDO procedure in patients with T2DM and its effect on MASLD.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2031-03-31 -> 2031-08-30 2026-06-25
minor Completion pushed: 2033-03-31 -> 2033-08-30 2026-06-25
Trial Details
NCT Number NCT07390422
Lead Sponsor Chinese University of Hong Kong
Conditions T2DM (Type 2 Diabetes Mellitus), MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Syndrome (MetS)
Enrollment 40 participants
Start Date 2026-09-01
Primary Completion 2031-08-30 (estimated)
Study Completion 2033-08-30 (estimated)
Updated on ClinicalTrials.gov 2026-06-24